Literature DB >> 2547882

Herpes zoster in an adult recipient of live attenuated varicella vaccine.

M R Hammerschlag1, A A Gershon, S P Steinberg, L Clarke, L D Gelb.   

Abstract

A healthy 30-y-old female physician who was immunized with two doses of live attenuated varicella vaccine developed a localized case of zoster involving the right T8-10 dermatomes 36 mo after vaccination. The virus isolated from her rash was an unusual wild-type of varicella-zoster virus. After immunization she developed detectable antibodies to varicella-zoster virus, but antibodies were no longer detectable after 20 mo. Six months before development of zoster, she was exposed to a patient with varicella; however, she did not develop a clinical illness although she again became seropositive. To date, this is the only reported case of zoster among 187 healthy adult vaccinees.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547882     DOI: 10.1093/infdis/160.3.535

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Authors:  Aruna P N Ambagala; Tammy Krogmann; Jing Qin; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

3.  Vaccination to prevent varicella and shingles.

Authors:  J Breuer
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

Review 4.  Tolerability of treatments for postherpetic neuralgia.

Authors:  Mark W Douglas; Robert W Johnson; Anthony L Cunningham
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization.

Authors:  Duane L Pierson; Satish K Mehta; Don Gilden; Randall J Cohrs; Maria A Nagel; D Scott Schmid; Stephen K Tyring
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

Review 6.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 7.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

Review 8.  Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.

Authors:  G S Goldman; P G King
Journal:  Vaccine       Date:  2012-06-01       Impact factor: 3.641

9.  Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG?

Authors:  Matthias Budt; Henrike Reinhard; Arndt Bigl; Hartmut Hengel
Journal:  Int Immunopharmacol       Date:  2004-09       Impact factor: 4.932

Review 10.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.